{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barwatt J"],"funding":["NIAID NIH HHS","Foundation for the National Institutes of Health"],"pagination":["e0013248"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12342302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(8)"],"pubmed_abstract":["Background
Several antigen-detection assays have been developed for the rapid diagnosis of talaromycosis, but their utility has been limited by a lack of commercial options. The aim of this study was to perform a head-to-head comparison of the performance of our in-house monoclonal antibody-based Mp1p antigen-detecting enzyme immunoassay (EIA) with its recently-developed commercial platform.Methods
In this diagnostic accuracy, retrospective, case-cohort study, we compared the sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-) of the commercial Wantai Mp1p EIA versus our in-house Mp1p EIA on paired plasma and urine samples from 424 hospitalized adults with advanced HIV disease, including 224 cases of proven talaromycosis, where Tala"],"journal":["PLoS neglected tropical diseases"],"pubmed_title":["Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis."],"pmcid":["PMC12342302"],"funding_grant_id":["U01AI169358","R01 AI143409","U01 AI169358","R01AI143409"],"pubmed_authors":["Cai JP","Brown L","Venugopalan S","Ly VT","Chan JF","Hoa NT","Le T","Yuen KY","Thu NTM","Barwatt J","Sambath HN","Gonzalez P"],"additional_accession":[]},"is_claimable":false,"name":"Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.","description":"Background
Several antigen-detection assays have been developed for the rapid diagnosis of talaromycosis, but their utility has been limited by a lack of commercial options. The aim of this study was to perform a head-to-head comparison of the performance of our in-house monoclonal antibody-based Mp1p antigen-detecting enzyme immunoassay (EIA) with its recently-developed commercial platform.Methods
In this diagnostic accuracy, retrospective, case-cohort study, we compared the sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-) of the commercial Wantai Mp1p EIA versus our in-house Mp1p EIA on paired plasma and urine samples from 424 hospitalized adults with advanced HIV disease, including 224 cases of proven talaromycosis, where Tala","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-04T22:01:41.98Z","creation":"2026-04-07T21:00:55.899Z"},"accession":"S-EPMC12342302","cross_references":{"pubmed":["40749024"],"doi":["10.1371/journal.pntd.0013248"]}}